Navigation Links
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Date:4/2/2009

PHILADELPHIA, April 2 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that it has filed a lawsuit in the U.S. District Court for the Southern District of New York against Natco Pharma Limited ("Natco") for infringement of two of Shire's patents: U.S. Patent No. 5,968,976 ("'976 Patent"); and U.S. Patent No. 7,381,428 ("'428 Patent");

The lawsuit was filed in response to an ANDA (Abbreviated New Drug Application) filed by Natco seeking FDA approval to market and sell generic versions of Shire's 500 mg, 750 mg, and 1 g FOSRENOL(R) (Lanthanum Carbonate) products.

Under the Hatch-Waxman Act, because Shire filed its patent infringement lawsuit within 45 days of receiving Natco's Paragraph IV notification letter, the FDA must refrain from approving Natco's ANDA for 30 months, or until a district court decision finding that the patents are invalid or not infringed, whichever occurs earlier. The stay on generic approval will expire on April 26, 2012 unless terminated earlier.

Shire has asserted the '976 and '428 patents based upon information provided to it by Natco. Shire will continue to evaluate the situation throughout the litigation and will take all necessary actions to protect its rights to the fullest extent possible. Shire has a robust patent estate and is confident that it will protect the FOSRENOL franchise.

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The announced sales ... the company is looking to expand in non-healthcare areas, ... The healthcare market research firm says that  Siemens is ... Information,s biennial survey of the IVD market , with ... change in its composition would likely affect IVD market ...
(Date:11/26/2014)... PMG Research, Inc. announced today the ... network of sites that provide clinical research services to pharmaceutical ... lives through its partnerships with large physician practices and integrated ... locations in the Southeastern United States and spans over 60 ... board will be held by: Dr. Robert Holmes, MD, ...
(Date:11/26/2014)... The Pittcon marketing department is pleased to ... mobile app, Pittcon 2015 . ... Store for iOS and Android devices and the Kindle ... and after the event. It acts as an all-inclusive ... sessions, Conferee Networking sessions and short courses. , The ...
(Date:11/26/2014)... 26, 2014 2014 Deep Research ... in-depth research report on the Global Palmitic Acid ... Palmitic Acid, basic information, including definition, classification, application, ... news analysis, etc. , For international and ... Acid market in China and other countries ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Pittcon Releases 2015 Mobile App 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3
... CAMBRIDGE, Mass., April 17, 2012 Inspiration Biopharmaceuticals, Inc. ... Application (BLA) to the U.S. Food and Drug Administration ... factor IX (rFIX) protein for the treatment and prevention ... Based on the terms of its agreement with ...
... OLDSMAR, Fla., April 16, 2012  Cryo-Cell International, Inc. ... world,s first private cord blood bank to separate and ... the first quarter ended February 29, 2012.   ... many changes that are taking place at the Company," ...
... Md., April 16, 2012  The Maryland Technology Enterprise ... University of Maryland $75K Business Plan Competition ... has spurred the commercialization of university technologies and ... (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO ) ...
Cached Biology Technology:Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 2Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 3Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 4Cryo-Cell Reports Financial Results for First Quarter 2012 2Cryo-Cell Reports Financial Results for First Quarter 2012 3Cryo-Cell Reports Financial Results for First Quarter 2012 491 EnTERPreneurs Enter, Nine Remain 291 EnTERPreneurs Enter, Nine Remain 391 EnTERPreneurs Enter, Nine Remain 4
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/11/2014)... Inc., a Chicago -based digital forensics ... of Yaniv Schiff from Senior Computer Forensics ... role as Director, he will lead company efforts to ... provide leadership within the company,s digital forensics practice area.  ... Schiff joined Forensicon in 2006 and has ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... National Park in northwest India, one thing was hard for biologist ... jackals. It was the squawks of peacocks in the throes of ... could hear a loud two-part whoop, the distinctive call that male ... a male announces that he,s ready to make his move by ...
... many different types of chemicals and plastics for the ... these materials are provided from petrochemical industry, using fossil ... concerns on the environmental problems and fossil resource availability, ... and materials from renewable non-food biomass through biorefineries. For ...
... Cancer Center study in this month,s edition of the ... potential treatment for melanoma, the most dangerous form of skin ... are expressed and which stay silent. Melanoma tends to lack ... a double negative," says Yiqun Shellman, PhD, investigator at the ...
Cached Biology News:Peacock love songs lure eavesdropping females from afar 2Production of 5-aminovaleric and glutaric acid by metabolically engineered microorganism 2Serendipity points to new potential target and therapy for melanoma 2